Archiv der Kategorie ‘Dr. Reddy’s Laboratories‘

RDY – Dr. Reddys Announces the Launch of Gemcitabine for Injection

Wednesday, den 27. July 2011

Dr. Reddy’s Q1 FY12 Financial Results

Wednesday, den 20. July 2011

Key Highlights Consolidated revenues are at Rs. 19.7 billion ($444 million) in Q1 FY12 versus Rs. 16.8 billion ($377 million) in Q1 FY11, year-on-year growth of 18%. Revenues from Global Generics for Q1 FY12 are at Rs. 14.4 billion ($323 million). Year-on-year growth of 21% mainly driven by North America generics and Russia. Revenues from […]

Dr. Reddy’s Laboratories

Wednesday, den 1. June 2011

Dr. Reddy’s Laboratories is an integrated pharmaceutical company and operates in business segments such as global generics, active ingredients and proprietary products. Dr Reddy’s March quarter results were higher-than-estimated with revenue growing 22.8% year-over-year, driven by robust growth of 67.6% in U.S. generics and 25.7% in Russia and CIS. The launch of generic fexofenadine pseudoephedrine […]

Dr Reddy’s says U.S. court clears generic Allegra sale

Wednesday, den 2. February 2011

“This is a positive for the company. Since Dr Reddy’s is the only player for this product, it should be able to do decent sales,” Sarabjit Kour Nangra, vice president of research and who tracks the sector at Angel Broking said. Dr. Reddy’s Laboratories announced today that on Friday, 28 January 2011, the U.S. District […]

Dr Reddy’s Laboratories will start to see the benefits from its tie-up with GlaxoSmithKline in two or three years

Wednesday, den 2. February 2011

“Overall, it is a good relationship that is working well and going as predicted, but the financial impact is going to be seen only two to three years from now,” he told Reuters on the sidelines of the annual meeting of the World Economic Forum. “It takes time to develop the products and register them […]

Dr. Reddy’s Laboratories Ltd. (RDY) Q3 2011 Earnings Call

Wednesday, den 26. January 2011

The financial highlights are as follows. Consolidated revenues for the quarter are at $424 million and represent a year-on-year growth of 10% and a sequential growth of 2%. Revenues from our Global Generics business stand at $303 million for the quarter, representing a year-on-year growth of 16%. Revenues from the Pharmaceutical Services and Active Ingredients […]

Dr Reddy’s profit hurt by German unit, shares fall

Wednesday, den 26. January 2011

Dr Reddy’s Laboratories, India’s No. 2 drugmaker, swung to a profit in the third quarter but missed analysts’ estimates as sales at its German unit plunged. Sales in Europe, one of Dr Reddy’s largest markets, fell 18 percent, driven by a 33-percent drop in Germany, as its German unit Betapharm struggled with pricing pressure amid […]

Biosimilars – The Next Generic Honeypot

Tuesday, den 14. September 2010

Generic drugs are certainly a significant part of the landscape in the healthcare world. Not only do they save healthcare consumers (and their insurance companies) millions of dollars a year, but they are a thriving industry in their own right. Companies like India’s Dr. Reddy’s Laboratories (NYSE:RDY) and its nearly ten-fold larger rival Teva Pharmaceuticals […]

Dr Reddy’s forecasts low single digit revenue growth in FY10

Wednesday, den 20. January 2010

Chief Executive G.V. Prasad said the company expected to post a “low single digit” revenue growth in the fiscal year that ends in March, down from its previous forecast of a 10-percent growth over the previous year. “Our German business has contracted beyond our expectations and there is a little bit of slowdown in the […]

Dr Reddy’s posts $113 mln net loss in Q3

Wednesday, den 20. January 2010

Indian drug maker Dr Reddy’s Laboratories Ltd posted a 5.2 billion rupees consolidated loss ($113 million) in the December quarter, compared with a profit of 2.4 billion rupees in the year-ago period, missing forecasts. Dr Reddy’s, India’s second-biggest drug maker by sales, said in September it had voluntarily recalled four products from its key U.S. […]

Dr. Reddy’s (RDY) Downgrade from Hold to Sell – Analyst rating from Deutsche Bank

Tuesday, den 19. January 2010

Dr. Reddy’s downgraded by Deutsche Bank

Tuesday, den 19. January 2010

Transgene Biotek Sells Obesity Drug Technology License To Dr Reddy’s

Thursday, den 7. January 2010

Transgene Biotek Ltd. said Thursday it has sold the license for the manufacturing process of obesity drug orlistat to Dr. Reddy’s Laboratories Ltd.

Analyst rating from Credit Suisse – Upgrade Dr. Reddy’s ( RDY ) from Neutral to Outperform

Monday, den 26. October 2009